Achillion Pharmaceuticals Inc
300 George Street06511 New Haven , Connecticut
Biopharmaceutical company dedicated to bringing important new treatments to patients with infectious disease.
Achillion is an innovative biopharmaceutical company dedicated to bringing important new treatments to patients with infectious disease. The company is developing three clinical candidates for the treatment of chronic hepatitis C infection. ACH-1625 is a proprietary potent once-daily NS3 protease inhibitor that is currently in Phase II clinical development. ACH-2684 is a highly potent pan-genotypic inhibitor of HCV NS3 protease with pico-molar potency that is currently in Phase 1 clinical development. ACH-2928 and ACH-3102 are potent inhibitors of HCV NS5A that demonstrate pan-genotypic activity.